Rural Health Clinical Congress Spring 2025

CME/CE INFORMATION

Rural Health Clinical Congress Spring 2025

Saturday, May 17, 2025 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT

HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:

Step 1: Log In
Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
If you do not know your password, follow the link to reset it.
Step 2: Complete Evaluation(s)
Click the Evaluations link located in the gray navigation bar (under the event title). You will see a listing of the sessions. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.
Step 3: View and Print Certificate(s)
After you’ve completed the evaluations, click the Print Certificate button to view and print your CME/CE certificates.

For Pharmacists: Upon completion of the online evaluation(s), your credits will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluations and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Implementing Treatment Advances in Eosinophilic Esophagitis Care
Across All Ages in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AbbVie Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc., Rahway, NJ, USA; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

This session is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.25 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care physicians, nurse practitioners, physician assistants, nurses, and pharmacists who care for patients from rural and underserved communities.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:

Recognize the symptoms and clinical presentations of eosinophilic esophagitis (EoE) to facilitate the early recognition of patients who require further workup for a definitive diagnosis
Evaluate the efficacy and safety of current and emerging therapies for EoE
Apply current guideline recommendations and clinical evidence to improve management of EoE in rural primary care, including appropriate use of new and emerging therapies
Implement collaborative, patient-centered strategies to appropriately support patients with EoE residing in rural and underserved communities

FACULTY
Paul E. Feuerstadt, MD
Associate Clinical Professor of Medicine
Yale University School of Medicine
Managing Partner
PACT Gastroenterology Center
New Haven, CT

Cody A. Chastain, MD, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-25-039-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Paul E. Feuerstadt, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Ferring Pharmaceuticals, Inc., Nestlé Health Science, ProbioTech USA, LLC, Regeneron Pharmaceuticals, Inc., Sanofi, and Vedanta Biosciences, Inc.; speakers’ bureau member for Ferring Pharmaceuticals, Inc., Nestlé Health Science, Regeneron Pharmaceuticals, Inc., and Sanofi; grant/research support from Ellodi Pharmaceuticals, Ferring Pharmaceuticals, Inc., and Takeda Pharmaceuticals.

Cody A. Chastain, MD, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Breathe Better: Improving Access and Advancing COPD Care
in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

custom image

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:

Employ evidence-based strategies and best practices to assess, identify, and monitor symptoms and the risk of future exacerbations in patients with chronic obstructive pulmonary disease (COPD)
Evaluate the safety and efficacy of current and emerging biologic therapies for the management of COPD
Develop personalized treatment plans for patients with COPD based on the latest clinical evidence and guideline recommendations to reduce exacerbations and improve lung function
Implement strategies to improve COPD outcomes in rural and underserved settings, including patient education on smoking cessation, self-management tools, pulmonary rehabilitation, and telehealth interventions

FACULTY
Nicola A. Hanania, MD, MS
Professor of Medicine - Pulmonary
Director, Airways Clinical Research Center
Baylor College of Medicine
Chief of Pulmonary/Critical Care/Sleep Medicine
Ben Taub Hospital
Houston, TX

Cody A. Chastain, MD, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Pharmacotherapy credit for Advanced Practice Registered Nurses to be determined.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Nicola A. Hanania, MD, MS, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Chiesi USA, Inc., Genentech, Inc., GSK, Sanofi, and Verona Pharma; speakers’ bureau member for Regeneron Pharmaceuticals, Inc. and Sanofi; grant/research support from AstraZeneca Pharmaceuticals, Chiesi USA, Inc., Genentech, Inc., GSK, and Sanofi.

Cody A. Chastain, MD, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

IBD Care in Rural and Underserved Communities:
Collaborative Approaches to Address Disparities and Improve Patient Outcomes

Provided by Talem Health and RME Collaborative:

custom image

This session is supported by independent medical education grants from AbbVie Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:

Utilize evidence-based recommendations to screen and diagnose patients with inflammatory bowel disease (IBD)
Summarize current and emerging treatment options for IBD, including potential side effects and recommended follow-up care
Apply evidence-based treatment strategies for patients with IBD that reflect the latest clinical evidence and guideline recommendations
Employ multidisciplinary strategies to improve access to care and treatment for rural and underserved populations with IBD

FACULTY
Jordan E. Axelrad, MD, MPH
Associate Professor of Medicine
NYU Grossman School of Medicine
Co-Director, Inflammatory Bowel Disease Center
NYU Langone Health
New York, NY

Cody A. Chastain, MD, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jordan E. Axelrad, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., Adiso Therapeutics, bioMérieux, Bristol-Myers Squibb Company, Celltrion, Inc., Ferring Pharmaceuticals, Inc., Janssen Pharmaceuticals, Merck & Co. Inc., Pfizer, Inc., Sanofi, and Vedanta Biosciences, Inc.; grant/research support from BioFire Diagnostics and Genentech, Inc.

Cody A. Chastain, MD, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

Improving Identification and Management of Hyperlipidemia
in Rural and Underserved Communities

Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT

This initiative is co-supported by independent medical education grants from AbbVie Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc., Rahway, NJ, USA; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc. and Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

This session is supported by independent medical education grants from Merck & Co., Inc., Rahway, NJ, USA; and Novartis Pharmaceuticals Corporation.

CREDIT AVAILABLE

Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:

Discuss the role of lipoprotein(a) in risk assessment and management of cardiovascular disease
Summarize the efficacy and safety data of new and emerging non-statin lipid therapies for reducing lipids and cardiovascular events
Develop a personalized treatment plan for patients with hyperlipidemia, incorporating non-statin therapies and guided by current recommendations and clinical evidence
Employ a multidisciplinary, patient-centered approach to improve access to hyperlipidemia care and treatment in rural and underserved areas

FACULTY
Peter P. Toth, MD, PhD
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Adjunct Professor of Medicine, Division of Cardiology
Johns Hopkins University School of Medicine
Director of Preventive Cardiology
CGH Medical Center
Baltimore, MD

Cody A. Chastain, MD, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Peter P. Toth, MD, PhD, has disclosed the following relevant financial relationships: consultant/advisory board member for Merck & Co., Inc.; speakers’ bureau member for Amgen, Inc., Eli Lilly and Company, and Novo Nordisk A/S.

Cody A. Chastain, MD, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

CONTACT US
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.

MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

System checker: Must meet all requirements of BroadcastMed Live Events Platform
Operating system: Windows or Macintosh
Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
Hardware: computer, smartphone, or tablet
Broadband Internet connection: high-speed connection preferable

FEE INFORMATION
There is no fee for this educational activity.

COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.